First Horizon Pharmaceutical (NASDAQ:FHRX)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more First Horizon Pharmaceutical Charts. Click Here for more First Horizon Pharmaceutical Charts.](/p.php?pid=staticchart&s=N%5EFHRX&p=8&t=15)
SkyePharma and First Horizon Extend Agreement for Novel
Formulation of Fenofibrate
LONDON, Feb. 1 /PRNewswire-FirstCall/ -- SkyePharma PLC (NASDAQ:SKYE) ( LSE:
SKP) announces today that it has extended an agreement with First Horizon
Pharmaceutical Corporation ("First Horizon", Nasdaq: FHRX) originally signed in
May 2004 in connection with SkyePharma's novel formulation of fenofibrate,
currently under review by the US Food and Drug Administration ("FDA"). Subject
to FDA approval, the amended agreement would now permit First Horizon to launch
the novel fenofibrate product in the first half of 2005.
Michael Ashton, SkyePharma's Chief Executive Officer, said: "We are delighted
by this demonstration of First Horizon's continuing commitment."
SkyePharma PLC develops pharmaceutical products benefiting from world-leading
drug delivery technologies that provide easier-to-use and more effective drug
formulations. There are now nine approved products incorporating three from
SkyePharma's five technologies in the areas of oral, injectable, inhaled and
topical delivery, supported by advanced solubilisation capabilities. For more
information, visit http://www.skyepharma.com/.
Except for the historical information herein, the matters discussed in this
news release include forward-looking statements that may involve a number of
risks and uncertainties. Actual results may vary significantly based upon a
number of factors, which are described in SkyePharma's 20-F and other documents
on file with the SEC. These include without limitation risks in obtaining and
maintaining regulatory approval for existing, new or expanded indications for
its products, other regulatory risks, risks relating to SkyePharma's ability to
manufacture pharmaceutical products on a large scale, risks that customer
inventory will be greater than previously thought, risks concerning
SkyePharma's ability to manage growth, SkyePharma's marketing partners' ability
to market a pharmaceutical product on a large scale and manage their sales and
marketing organisation and maintain or expand sales and market share for its
products, risks relating to the ability to ensure regulatory compliance, risks
related to the research, development and regulatory approval of new
pharmaceutical products, risks related to research and development costs and
capabilities, market acceptance of and continuing demand for SkyePharma's
products and the impact of increased competition, risks associated with
anticipated top and bottom line growth and the possibility that upside
potential will not be achieved, competitive products and pricing, and risks
associated with the ownership and use of intellectual property rights.
SkyePharma undertakes no obligation to revise or update any such
forward-looking statement to reflect events or circumstances after the date of
this release.
For further information please contact:
SkyePharma PLC +44 207 491 1777
Michael Ashton, Chief Executive Officer
Peter Laing, Director of Corporate Communications +44 205-491 5124
Sandra Haughton, US Investor Relations +1 212 753 5780
Buchanan Communications +44 207 466 5000
Tim Anderson / Mark Court
DATASOURCE: SkyePharma PLC
CONTACT: Michael Ashton, Chief Executive Officer, +44-207-491-1777,
Peter Laing, Director of Corporate Communications, +44-205-491-5124,
Sandra Haughton, US Investor Relations, +1-212-753-5780, all of SkyePharma
PLC, Tim Anderson and Mark Court of Buchanan Communications,
+44-207-466-5000 for SkyePharma PLC
Web site: http://www.skyepharma.com/